Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non-Current Assets for 7 consecutive years, with $153.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 22.42% to $153.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $618.7 million through Dec 2025, up 62.6% year-over-year, with the annual reading at $153.6 million for FY2025, 22.42% up from the prior year.
  • Non-Current Assets for Q4 2025 was $153.6 million at 4D Molecular Therapeutics, up from $111.6 million in the prior quarter.
  • The five-year high for Non-Current Assets was $183.2 million in Q1 2025, with the low at $5.6 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $77.9 million, with a median of $71.2 million recorded in 2021.
  • The sharpest move saw Non-Current Assets skyrocketed 1612.9% in 2021, then tumbled 57.48% in 2022.
  • Over 5 years, Non-Current Assets stood at $97.2 million in 2021, then plummeted by 57.48% to $41.3 million in 2022, then rose by 4.76% to $43.3 million in 2023, then surged by 189.71% to $125.5 million in 2024, then grew by 22.42% to $153.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $153.6 million, $111.6 million, and $170.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.